High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey

Table 1 Comparisons of demographic and clinical characteristics of patients in the three antipsychotic groups

		Olanzapine (N = 356)	Risperidone (N = 529)	Aripiprazole (N = 222)	p-value
Age	years	56.4 ± 14.0	60.2 ± 13.2	54.8 ± 15.2	< 0.001
Females (males)		158 (198)	243 (286)	115 (107)	0.201
Outpatients (inpatients)		138 (218)	194 (335)	101 (121)	0.077
BMI	kg/m²	23.2 ± 4.1	23.5 ± 4.5	23.5 ± 5.1	0.516
Waist circumference	cm	84.0 ± 11.5	84.8 ± 11.7	83.4 ± 14.1	0.297
Systolic blood pressure	mmHg	124.5 ± 18.9	122.7 ± 17.3	123.9 ± 19.1	0.355
Diastolic blood pressure	mmHg	77.2 ± 12.3	75.0 ± 12.5	74.9 ± 13.0	0.025
HDL-cholesterol	mg/dL	54.3 ± 18.6	55.4 ± 17.9	57.5 ± 17.9	0.126
CP-equivalent dosage of current AAP	mg	516.1 ± 261.7	420.8 ± 273.4	402.1 ± 231.7	< 0.001
Concomitant drugs
Antidepressant		1	0	0
Mood stabilizer		6	11	3
Benzodiazepines		7	13	2
Anticholinergic drug		0	9	0

Data are shown as the mean ± SD or number of subjects
Age, BMI, waist circumference, systolic blood pressure, diastolic blood pressure, HDL-cholesterol, and CP-equivalent dosage of current AAP were compared among the three antipsychotics groups. The chi-square test was performed to analyze sex and outpatients (inpatients)
BMI body mass index, HDL high-density lipoprotein, CP chlorpromazine, AAP atypical antipsychotic

ISSN: 1471-244X